synairgen.png
Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2 COVID-19 Trial
October 20, 2021 07:00 ET | Synairgen plc
Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2 COVID-19 Trial Southampton, UK – 20 October...
synairgen.png
Non-Executive Director Appointment
September 30, 2021 07:00 ET | Synairgen plc
Synairgen plc(‘Synairgen’ or the ‘Company’) Non-Executive Director Appointment Southampton, UK – 30 September 2021: Synairgen plc (LSE: SNG), the drug discovery, development and commercialisation...
synairgen.png
Interim results for the six months ended 30 June 2021
September 30, 2021 07:00 ET | Synairgen plc
Synairgen plc(‘Synairgen’ or the ‘Company’) Interim results for the six months ended 30 June 2021 Scaling up and preparing for Phase III COVID-19 trial data read-out Webcast today at 13:00 BST ...
synairgen.png
Non-Executive Director Appointment
September 30, 2021 02:02 ET | Synairgen plc
Synairgen plc(‘Synairgen’ or the ‘Company’) Non-Executive Director Appointment Southampton, UK – 30 September 2021: Synairgen plc (LSE: SNG), the drug discovery, development and commercialisation...
synairgen.png
Interim results for the six months ended 30 June 2021
September 30, 2021 02:01 ET | Synairgen plc
Synairgen plc(‘Synairgen’ or the ‘Company’) Interim results for the six months ended 30 June 2021 Scaling up and preparing for Phase III COVID-19 trial data read-out Webcast today at 13:00 BST ...
synairgen.png
Synairgen announces results of in vitro studies showing antiviral activity of interferon beta against key SARS-CoV-2 variants
May 24, 2021 07:00 ET | Synairgen plc
Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces results of in vitro studies showing antiviral activity of interferon beta against key SARS-CoV-2 variants SNG001...
synairgen.png
Synairgen announces results of in vitro studies showing antiviral activity of interferon beta against key SARS-CoV-2 variants
May 24, 2021 02:00 ET | Synairgen plc
Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces results of in vitro studies showing antiviral activity of interferon beta against key SARS-CoV-2 variants SNG001...
synairgen.png
Preliminary results for the year ended 31 December 2020
May 12, 2021 07:00 ET | Synairgen plc
Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Preliminary results for the year ended 31 December 2020 Significant progress continues towards a treatment for COVID-19 ...
synairgen.png
Preliminary results for the year ended 31 December 2020
May 12, 2021 02:00 ET | Synairgen plc
Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Preliminary results for the year ended 31 December 2020 Significant progress continues towards a treatment for COVID-19 Southampton, UK –...
synairgen.png
Synairgen announces data from Home Cohort of SG016 Phase II trial of inhaled interferon beta in COVID-19 patients and encouraging combined data for whole SG016 trial
April 30, 2021 07:00 ET | Synairgen plc
Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces data from Home Cohort of SG016 Phase II trial of inhaled interferon beta in COVID-19 patients and encouraging...